Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies ...
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company dedicated to discovering and developing novel oral therapeutics for chronic diseases with significant unmet medical needs. The company's primary investigational drug, GSBR-1290, is an orally administered biased small molecule agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), a validated target for managing ...Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company dedicated to discovering and developing novel oral therapeutics for chronic diseases with significant unmet medical needs. The company's primary investigational drug, GSBR-1290, is an orally administered biased small molecule agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), a validated target for managing type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral small molecule programs targeting different G-protein-coupled receptors (GPCRs) for pulmonary and cardiovascular conditions, including ANPA-0073 (apelin receptor agonist) and LTSE-2578 (LPA1 receptor antagonist) for idiopathic pulmonary fibrosis. Founded in 2016 by Dr. Raymond C. Stevens, a pioneer in structure-based drug discovery, the company employs a structure-based approach to design orally bioavailable small molecules, aiming to offer more accessible and convenient treatment options compared to injectable biologics. Headquartered in South San Francisco, California, the company became public in 2023 and is listed on NASDAQ under the ticker GPCR. With approximately 220 employees, it focuses on R&D, with no revenue to date, as typical for a clinical-stage biotech. Financially, the company maintains a strong cash position (current ratio >20) and has raised capital through public offerings to fund its pipeline. Key milestones include positive Phase 2b results for its obesity candidate, highlighting its potential in the competitive GLP-1 market. The company's vision is to harness GPCR biology and structure-based design to create a new class of oral therapies that can transform patient care in metabolic and pulmonary diseases.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-141.2M
-15.2%
-39.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-225.8M
-91.5%
-952.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.4%
-4.2%
+14.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
24.81x
+0.3%
-20.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
